Skip to content

The Effect of Polynucleotide on Facial Skin Microbiome

The Effect of Polynucleotide on Facial Skin Microbiome

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260701011
Enrollment
40
Registered
2026-07-01
Start date
2026-06-09
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy population polynucleotide, microbiome, skin rejuvenation

Interventions

20 mg/mL of polynucleotide intradermally injection, 0.05 mL per injection point using prefilled syringe and 33-gauze needle, 1 mL each anterior medial cheeks, total 2 mL
Experimental Procedure/Surgery
Polynucleotide injection

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
25 Years to 45 Years

Inclusion criteria

Inclusion criteria: Participants who are interested in skin rejuvenation

Exclusion criteria

Exclusion criteria: 1. Pregnancy, possibly pregnancy or lactating, 2. Known allergies to marine products or polynucleotides, neuromuscular disorders, immunosuppression, or any severe systemic illness, 3. Active skin infection or inflammation including severe acne, dermatitis, or rosacea on the face, 4. History of systemic antibiotics, antifungals, or steroids for at least 4 weeks prior to the study, 5. History of retinoids or antibiotics applied to the face at least 4 weeks prior to the study, 6. History of botulinum toxin injection or mesotherapy within 6 months on the measured area, 7. History of fillers, fat grafting, thread lifting, energy-based treatment within 6 months on the measured area?, 8. History of prebiotic or oral supplements at least 4 weeks priors to the study

Design outcomes

Primary

MeasureTime frame
Alternation in skin microbiome diversity and composition At week 2, 4, 8, 12 Skin sample

Secondary

MeasureTime frame
Skin pore At week 2, 4, 8 , 12 Antera 3D,Skin texture At week 2, 4, 8, 12 Antera 3D,Wrinkle At week 2, 4, 8, 12 Antera 3 D,Erythema At week 2, 4, 8, 12 Antera 3D,Pigment At week 2, 4, 8, 12 Antera 3D,Hydration At week 2, 4, 8, 12 Cutometer,Elasticity At week 2, 4, 8, 12 Cutometer,Transepidermal water loss At week 2, 4, 8, 12 Tewameter,Sebum level At week 2, 4, 8, 12 Sebumeter,Skin pH At week 2, 4, 8, 12 Skin pH-meter,Skin improvement evaluation At week 2, 4, 8, 12 Photo and evaluation surveys,Adverse events during the study Evaluation form

Countries

Thailand

Contacts

Public ContactJitlada Meephansan

Chulabhorn International College of Medicine Thammasat University

kae_mdcu@yahoo.com66972468497

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026